Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ultragenyx Pharmaceutical (RARE) EBT Margin: 2016-2025

Historic EBT Margin for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Sep 2025 value amounting to -112.26%.

  • Ultragenyx Pharmaceutical's EBT Margin fell 1676.00% to -112.26% in Q3 2025 from the same period last year, while for Sep 2025 it was -91.46%, marking a year-over-year increase of 1588.00%. This contributed to the annual value of -101.31% for FY2024, which is 3881.00% up from last year.
  • Ultragenyx Pharmaceutical's EBT Margin amounted to -112.26% in Q3 2025, which was down 63.95% from -68.47% recorded in Q2 2025.
  • Over the past 5 years, Ultragenyx Pharmaceutical's EBT Margin peaked at -68.47% during Q2 2025, and registered a low of -263.30% during Q3 2022.
  • Moreover, its 3-year median value for EBT Margin was -107.52% (2025), whereas its average is -116.48%.
  • The largest annual percentage gain for Ultragenyx Pharmaceutical's EBT Margin in the last 5 years was 19,010bps (2021), contrasted with its biggest fall of 18,193bps (2021).
  • Over the past 5 years, Ultragenyx Pharmaceutical's EBT Margin (Quarterly) stood at -149.63% in 2021, then crashed by 32bps to -149.95% in 2022, then skyrocketed by 5,034bps to -99.61% in 2023, then skyrocketed by 1,870bps to -80.91% in 2024, then slumped by 1,676bps to -112.26% in 2025.
  • Its EBT Margin was -112.26% in Q3 2025, compared to -68.47% in Q2 2025 and -107.52% in Q1 2025.